High-speed centrifugation to enable anti-Xa testing on lipemic (fatty) blood samples
Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma
This will test whether spinning fatty (lipemic) blood samples very fast helps the lab get accurate anti-Xa measurements for adults on anti-Xa anticoagulant medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07200674 on ClinicalTrials.gov |
What this trial studies
Many anti-Xa assays rely on spectrophotometric readings that can be distorted when a sample is lipemic, a problem affecting a small percentage of routine samples. This observational project uses routine adult anti-Xa samples, artificially overloaded with lipids when needed, to see if a high-speed centrifugation step (10,800g for 10 minutes) clears the interference. Samples will come from patients already anticoagulated with agents monitored by anti-Xa (UFH, LMWH, fondaparinux, danaparoid, apixaban, rivaroxaban) and processed at the CHU de Strasbourg hematology laboratory. Samples with pre-existing high baseline lipemia or insufficient volume are excluded.
Who should consider this trial
Good fit: Adults (≥18) who are receiving anti-Xa anticoagulants and have blood samples sent to the CHU de Strasbourg Hematology Laboratory for anti-Xa measurement are the intended participants.
Not a fit: Patients with naturally high baseline lipemia or samples that do not have enough volume are excluded and are unlikely to benefit from this process.
Why it matters
Potential benefit: If successful, labs could obtain reliable anti-Xa results from lipemic samples, reducing repeat blood draws and improving anticoagulant dosing decisions.
How similar studies have performed: There are small laboratory reports suggesting centrifugation can reduce lipemia interference, but no large validated studies specifically confirm high-speed centrifugation reliably restores anti-Xa measurements.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥ 18 years) * Patient anticoagulated with an anti-Xa (UFH, LMWH, fondaparinux, danaparoid, apixaban, rivaroxaban) * Sample sent to the HUS Hematology Laboratory and analyzed for measurement of the anti-Xa activity of an anticoagulant as part of routine care Exclusion Criteria: * Patient with a basal lipidemic sample * Sample of insufficient volume
Where this trial is running
Strasbourg
- Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Agathe HERB, PharmD
- Email: agathe.herb@chru-strasbourg.fr
- Phone: 33 3 88 12 75 53
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.